Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1-Targeted CAR-T Cells in Relapsed/Refractory Multiple Myeloma
NCT07809594Phase 1Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS1-targeted CAR-T cells in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicities at 28 days and Treatment-Related Adverse Events at 28 days. Started Jul 2023; status: active, not recruiting.
02
Drugs
CS1-targeted CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07809594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809594.